We recently described a sensitive and specific assay that detects the fusion of HIV-1 virions to a broad range of target cells, including primary CD4 cells. This assay involves the use of virions containing h-lactamase-Vpr (BlaM-Vpr) and the loading of target cells with CCF2, a fluorogenic substrate of h-lactamase. Since Vpr strongly associates with the viral core, uncoating of the viral particle might be required for effective cleavage of CCF2 by BlaM-Vpr. Here, we show that BlaM-Vpr within mature viral cores effectively cleaves CCF2, indicating that this assay measures virion fusion independently of uncoating. We also show that wildtype and Nef-deficient HIV-1 virions fuse with equivalent efficiency to HeLa-CD4 cells, SupT1 T cells, and primary CD4 T cells. Since Nef enhances cytoplasmic delivery of viral cores and increases viral infectivity, these findings indicate that Nef enhances an early post-fusion event in the multistep process of viral entry. Possible sites of Nef action include enlargement of the fusion pore, enhanced uncoating of viral particles, and more efficient passage of viral cores through the dense cortical actin network located immediately beneath the plasma membrane.
Introduction
Human immunodeficiency virus type 1 (HIV-1) principally infects CD4-expressing T lymphocytes, monocytes/ macrophages, dendritic cells, and microglial cells in vivo. The entry of HIV-1 virions into these target cells requires the initial interaction of the viral envelope protein with two cell-surface receptors: CD4 and either CCR5 or CXCR4, which function as coreceptors for entry of R5-and X4-tropic viruses, respectively. The HIV-1 envelope protein initiates viral entry by undergoing a succession of conformational changes triggered by its interplay with CD4 and the coreceptors (Berger et al., 1999) . These events lead to the fusion of viral and host membranes. Once fusion has occurred, uncoating takes place. Although this process is poorly understood, it likely involves the phosphorylation of the viral capsid protein (Cartier et al., 1999) , which may be mediated by the catalytic subunit of the cellular protein kinase A (Cartier et al., 2003) and facilitated by cyclophilin A (Franke et al., 1994) . Both viral uncoating and passage of the viral cores through the dense cortical actin network are required for delivery of the viral reverse transcription complex/preintegration complex into the cytoplasm.
Among its many functions [for review, see (Arora et al., 2002; Greene and Peterlin, 2002; Piguet and Trono, 1999) ], the HIV-1 Nef protein increases the infectivity of HIV-1 by acting at an early step in the viral life cycle through both CD4-dependent and CD4-independent mechanisms. These changes in infectivity require the expression of Nef in the virus-producing cells, even though the effects are manifested in the subsequent target cells (Aiken and Trono, 1995; Chowers et al., 1995; Miller et al., 1995) . The CD4-dependent changes are mediated through the downregulation of surface CD4 expression in the virus-producing cell, which leads either to more efficient detachment of virions or to the release of virions containing greater quantities of the surface gp120 envelope (Lama et al., 1999; Ross et al., 1999) .
The CD4-independent mechanism through which Nef enhances HIV-1 infectivity is less well understood. Nef is incorporated into HIV-1 viral particles (Aiken and Trono, 1995; Bukovsky et al., 1997; Miller et al., 1997; Welker et al., 1996) but is cleaved by the HIV-1 protease, making a role for intravirion full-length Nef less likely (Bukovsky et al., 1997; Miller et al., 1997; Welker et al., 1996) . Early studies revealed that reverse transcription is impaired in virions produced in the absence of Nef, suggesting that Nef acts at an early step in the retroviral life cycle (Aiken and Trono, 1995; Chowers et al., 1995; Schwartz et al., 1995) . The in vitro induction of endogenous reverse transcription restores the infectivity of Nef-deficient virions (Khan et al., 2001) , although this reaction is associated with partial disassembly of the HIV-1 core. Thus, an effect of Nef before reverse transcription cannot be ruled out.
When viral entry is redirected through the endocytic pathway by pseudotyping virions with the vesicular stomatitis virus-G protein (VSV-G), the infectivity-enhancing effects of Nef are lost (Aiken, 1997; Chazal et al., 2001; Luo et al., 1998) . The density of either surface CD4 on the target cells or envelope protein on virions also modulates the extent to which Nef enhances viral infectivity (Tobiume et al., 2001 ). These results argue that Nef acts at an early step in the viral entry pathway before reverse transcription. We recently demonstrated that Nef increases cytoplasmic delivery of p24
Gag (Schaeffer et al., 2001) . However, these results did not distinguish between an effect of Nef at the level of virion fusion and at an early post-fusion step in the entry pathway leading to effective delivery of capsid proteins into the cytoplasm. The recent finding that Nef expression increases the cholesterol content of the HIV-1 virion membrane (Zheng et al., 2001 (Zheng et al., , 2003 coupled with the fact that cholesterol can influence the entry of enveloped viruses (Rawat et al., 2003) prompted us to examine whether Nef enhances the fusion of HIV-1 virions to target cells. Such an effect at the level of fusion could underlie the Nef-dependent increase in cytosolic delivery of viral cores we described previously (Schaeffer et al., 2001) .
To test whether Nef alters the fusion of HIV-1 virions, we developed a virion-based fusion assay (Cavrois et al., 2002 (Cavrois et al., , 2004 . This assay is based on the incorporation of a hlactamase-Vpr (BlaMÀVpr) protein chimera into the virion and the subsequent transfer of this chimera into the target cell as a result of fusion. Successful transfer can be monitored by the enzymatic cleavage of the CCF2-AM dye, a fluorescent substrate of h-lactamase (BlaM), loaded into the target cells. Cleavage of the h-lactam ring in CCF2 by h-lactamase alters the fluorescence emission spectrum of the dye from green (520 nm) to blue (447 nm) (Zlokarnik et al., 1998) . This change can be detected at the single-cell level by fluorescence microscopy or flow cytometry. Of note, this assay detects HIV-1 virion fusion and not virion endocytosis (Cavrois et al., 2002) . However, since Vpr strongly associates with the p6 component of Gag, the BlaM-Vpr chimera likely resides within the viral core. In such a scenario, particle uncoating might be required for cleavage of CCF2 by BlaM-Vpr. If so, the virion-based assay would be affected by events altering both fusion and uncoating.
In this study, we determined whether uncoating of the viral particle is required to generate a positive signal in the fusion assay. We also assessed whether the enhanced delivery of cytoplasmic p24
Gag and increased infectivity induced by Nef reflect events occurring at the level of fusion.
Results
The virion-based fusion assay detects fusion independently of viral uncoating
The BlaM-Vpr chimera is incorporated into the virion through the interaction of Vpr with the p6 component of Gag (Paxton et al., 1993) . This physical association suggests that BlaM-Vpr may reside in the viral core. Studies were undertaken to investigate the localization of BlaM-Vpr within HIV-1 virions. As expected, gp41 was not detected in these isolated HIV-1 cores, and both subunits of reverse transcriptase (p51 and p66) and Vpr remained associated with the core (Fig. 1A) . As previously reported (Welker et al., 2000) , only a fraction with p24
Gag purified with the cores. Our results indicate that BlaM-Vpr remains associated with the HIV-1 cores.
To determine if BlaM-Vpr associated with the HIV-1 core can cleave CCF2, purified cores were incubated for 3 or 6 h at room temperature with the nonesterified version of CCF2 (CCF2-AF, Invitrogen). The ratio of blue to green fluorescence increased in the presence of the HIV-1 cores (Fig. 1B) . To ensure that the BlaM activity in these core preparations did not result from a enzyme leakage or contamination by uncoated cores, we compared the BlaM activity in intact cores and in cores disassembled by sonication. BlaM activity was identical in both cases (Fig.  1B) . To control for the efficiency of core disassembly, we measured BlaM activity released from the sonicated cores into the supernatant following centrifugation (Fig. 1C) . BlaM activity was only detected in the supernatant of the sonicated cores, not the intact cores, indicating that sonication was effective in disassembling HIV-1 cores. Finally, to control for the integrity of untreated cores after a 6-h incubation at room temperature, we determined the percentage of p24
Gag present in the pellet after high-speed centrifugation of core-containing suspensions. More than
97% of p24
Gag was present in the pellet when the cores were untreated, but no pelletable p24
Gag was observed in the negative control (HIV-1 cores treated with 0.1% Triton X-100; data not shown). These results indicate that BlaMVpr associated with the HIV-1 core can cleave CCF2. Therefore, uncoating is not required to generate a positive signal in the HIV-1 virion-based fusion assay.
HIV-1 virions produced in presence and in absence of Nef fuse equivalently to HeLa-CD4 cells
To further study the precise mechanism by which Nef increases the cytoplasmic delivery of viral cores and enhances infectivity, wildtype and Nef-deficient virions containing BlaM-Vpr were produced. First, we assessed whether equivalent amounts of BlaM-Vpr were incorporated into these virions ( Fig. 2A) . Pelleted virions were lysed and immunoblotted with rabbit polyclonal anti-Vpr (Jenkins et al., 1998) or mouse monoclonal anti-p24
Gag antibodies for standardization of the virion preparations. The BlaM-Vpr chimera was comparably incorporated into wildtype and Nef-deficient virions ( Fig. 2A) .
Next, we investigated the fusion of wildtype and Nefdeficient X-4 tropic virions to HeLa-CD4 cells (Cavrois et al., 2002) . The cells were plated in chamber slides and infected for 2 h at 37 8C in the presence or absence of AMD3100, an inhibitor of CXCR4-dependent virion entry (Fig. 2B) . CCF2-AM, the membrane-permeable ester form of the BlaM substrate, was then loaded into target cells, and enzymatic cleavage was allowed to proceed for 7 h at room temperature. The cells were then fixed in 1.2% paraformaldehyde and analyzed by fluorescence microscopy (Fig.   2B ). As expected, no bblueQ cells, indicative of HIV-1 virion fusion, were detected in either the mock-infected or AMD3100-treated samples. However, comparable numbers of blue cells were detected in cultures infected with wildtype or Nef-deficient virions. Similar results were obtained with R5-tropic virions in HeLa-CD4 cells expressing CCR5 (data not shown). These findings indicate that Nef does not influence the fusion of HIV-1 virions to HeLa-CD4 cells.
Nef enhances HIV-1 infectivity but not fusion in human SupT1 T cells
We next assessed the fusion of wildtype and Nefdeficient virions to human CD4 + SupT1 cells. To ensure that the fusion reaction was measured within the dynamic range of the assay, SupT1 cells were infected with serial dilutions of the two viral stocks. The effects of Nef on infectivity of HIV-1 were assessed in parallel within the same infected population of cells. Fusion was measured by flow cytometry 2 h after infection, and productive viral infection of these cells was assessed 48 h later by intracellular immunostaining with FITC-conjugated antip24
Gag antibodies (Cavrois et al., 2002) . In cells inoculated with 100 ng of p24 Gag (Fig. 3A) , slightly more Nef-deficient virions than wildtype virions fused to SupT1 cells (36% versus 28%). Conversely, fewer target cells were productively infected by Nef-deficient virions than by wildtype virions (10.5% versus 25%). At all of the dilutions tested, despite a consistent decrease in the number of productively infected cells, fusion of Nef-deficient virions to SupT1 target cells was either equivalent to or slightly better than (Szilvay et al., 1992) , anti-gp41 (Gorny et al., 1989), anti-p24 Gag (Coulter), and anti-Vpr (Jenkins et al., 1998) antibodies. Note the presence of BlaM-Vpr in HIV-1 core. BlaM-Vpr and Vpr migrate at 41 and 11 kDa, respectively. (B) Measurement of BlaM activity associated with purified cores. Purified cores were sonicated or left intact and incubated with CCF2-FA for 3 or 6 h at room temperature. The increase in the ratio of blue to green fluorescence was similar in both preparations. (C) Measurement of BlaM activity released into the supernatant. Untreated or sonicated cores were pelleted, and BlaM activity released into the supernatant was measured after 3 and 6 h of incubation with CCF2-FA at room temperature. BlaM activity was found only in the supernatant of cultures containing sonicated cores.
that of wildtype virions (Fig. 3B) . Thus, Nef does not appear to enhance virion infectivity through effects at the level of fusion in SupT1 cells.
Nef enhances HIV-1 infectivity at a post-fusion step in primary T cells
Although Nef exerts only a modest effect on the ability of HIV-1 to spread in T-cell lines, it consistently enhances HIV-1 replication in primary CD4 T lymphocytes, particularly when the cells are stimulated after infection (Miller et al., 1994; Spina et al., 1994) . Thus, we assessed the effects of Nef on viral fusion in unactivated peripheral blood lymphocytes (Fig. 4 ). An aliquot of these cell cultures was stimulated with phytohemagglutinin (5 Ag/ml) and interleukin-2 (20 IU/ml) to allow completion of the retroviral life cycle. Productive viral infection was assessed 4 days later by intracellular immunostaining with FITCconjugated anti-p24
Gag antibodies (Fig. 4) . To identify T lymphocytes, the fusion assay was combined with an anti-CD3 immunostaining step. As expected, the addition of AMD3100, the X4-tropic HIV-1 inhibitor, blocked both the fusion and replication of NL4-3 viruses, while treatment with AZT had no inhibitory effect on fusion but blocked productive infection. Similar levels of fusion were observed with wildtype and Nef-deficient virions (1.39% versus 1.73%). However, in the same cultures after 4 days of stimulation that allowed a second round of replication to occur, Nef significantly increased the number of productively infected cells (4.68% versus 1.15%). Similar results were obtained with phytohemagglutinin-activated peripheral blood leukocytes; however, the Nef phenotype was less pronounced (data not shown), consistent with previous studies (Spina et al., 1994) . These findings indicate that Nef does not enhance HIV-1 infectivity in primary CD4 T lymphocytes by increasing virion fusion to these cellular targets.
Discussion
This study shows that the HIV-1 virion-based fusion assay measures fusion independently of viral particle uncoating, as demonstrated by the ability of isolated HIV-1 cores containing BlaM-Vpr to readily cleave the CCF2 fluorescent substrate. We also showed that the enhanced cytoplasmic delivery of viral cores produced by Nef does not reflect changes at the level of virion fusion in primary CD4 T lymphocytes or in the various cell lines we studied.
In contrast to our findings, a recent study indicated that Nef increases HIV-1 fusion to MAGI R5 cells by twofold (Day et al., 2004) . These results could reflect the type of target cells used. Some cell lines, including MAGI cells, have endogenous BlaM activity, which likely results from a leakage of the prokaryote promoter of the plasmid introduced in these cells (Cavrois et al., 2004) . Such activity might have altered the position of the bblue cellQ gate and led to a misinterpretation of the data. However, our findings agree with Tobiume et al. (2003), who found that Nef does not affect the efficiency of fusion of HIV-1 virions to HeLa-CD4 or MT4 cells. Therefore, Nef appears to act at an early post-fusion step in the viral entry pathway.
Since our virion-based assay measures fusion independently of uncoating, one possibility is that Nef leads to more efficient virion uncoating. However, this scenario is not likely, since Nef does not appear to alter the stability of viral cores in vitro (Forshey and Aiken, 2003) . Alternatively, Nef may facilitate the passage of viral cores through the dense subcortical actin network beneath the plasma membrane (Campbell and Hope, 2004) . Trapping of Nefdeficient virions in this actin network could lead to fractionation of capsid proteins in the membrane-and vesicle-rich pellet after ultracentrifugation. This might account for diminished cytoplasmic delivery of p24
Gag in the absence of Nef (Schaeffer et al., 2001 ). The fact that VSV-G pseudotyping relieves the requirement for Nef could be explained by the ability of endosomes to traffic through the cortical actin network. However, this model would not appear to account for the influence of the density of either surface CD4 on target cells or envelope protein on virions on Nef enhancement of viral infectivity described by Tobiume et al. (2001) .
A third possibility is that Nef acts after fusion but before uncoating by facilitating enlargement of the fusion pore. Since the plasma membrane and the subcortical actin network are closely linked, drug-induced destabilization of this network could alter the organization of the plasma membrane, which could in turn enlarge the fusion pore and enhance the passage of HIV-1 cores into the cell. Enlargement of the fusion pore could also be affected by high concentrations of CD4 or coreceptor in the target cells or envelope on the virions, which would promote the initiation of fusion at multiple contact points. Under these conditions, dependence on Nef might decrease, as found by Tobiume et al. (2001) . The higher cholesterol content of wildtype virions compared to Nefdeficient virions (Zheng et al., 2001 (Zheng et al., , 2003 might also contribute to more effective opening of the fusion pore, as cholesterol has been proposed as a key factor facilitating the growth of the fusion pore (Razinkov and Cohen, 2000) .
Although the precise site of Nef action remains unclear, our studies further refine its site of action to an early postfusion step that limits the effective delivery of HIV-1 cores into the cytoplasm. Nef-mediated bypass of this block appears to be required for effective reverse transcription and the resultant increase in viral infectivity.
Materials and methods

Viral production
HIV-1 virions containing BlaM-Vpr were produced by cotransfection of 293T cells (plated in 175 cm 2 flasks) with pNL4-3 proviral DNA (60 Ag) or pNL4-3DNef, pCMVBlaM-Vpr (20 Ag), and pAdVAntage vectors (10 Ag) (Promega). After 24 h of culture at 37 8C, the viruscontaining supernatant was centrifuged at low speed to remove cellular debris and then ultracentrifuged at 72,000 Â g for 90 min at 4 8C to sediment viral particles. The virionenriched pellet was resuspended in Dulbecco's modified Eagle medium (DMEM) and aliquoted for storage at À80 8C. All transfections were performed with calcium phos- phate to precipitate DNA. Viral stocks were normalized to p24
Gag content, measured in an enzyme-linked immunosorbent assay (NEN Life Science Products).
Purification of HIV-1 cores
HIV-1 cores were purified as described (Welker et al., 2000) with minor modifications. Viral particles in the supernatant of 293T cells transfected as described above were concentrated by centrifugation (100,000 Â g for 2 h at 4 8C) through a cushion formed with 2 ml of 6% iodixanol (Optiprep, Gibco BRL) diluted in phosphate-buffered saline (PBS). The pellet was washed and resuspended in 120 Al of PBS. Subsequently, 40 Al of this viral suspension was mixed with an equal volume of 200 mM NaCl, 100 mM morphoinepropanesulfonic acid (MOPS; pH 7.0). Virions were either left intact or lysed by adding Triton X-100 (final concentration, 0.5%). Intact virions or HIV-1 cores were recovered by centrifugation at 13,800 Â g for 8 min at 4 8C. The pellets were washed twice in 100 mM NaCl and 50 mM MOPS (pH 7.0), and protein composition was analyzed by immunoblotting with antibodies against gp41, reverse transcriptase (p66 RT or p51 RT ), or Vpr.
Analysis of the b-lactamase activity of BlaM-Vpr
HIV-1 cores purified from 240 Al of concentrated virion preparations were diluted in 4 ml of 100 mM NaCl and 50 mM MOPS (pH 7.0). Half of the resulting suspension was sonicated on ice (10-s pulses for 5 min), and half was kept at 4 8C. CCF2-FA, the fluorescent substrate of BlaM (Invitrogen), was then added to both suspensions (final concentration, 5 AM). BlaM activity was measured after 3 and 6 h of incubation at room temperature by determining the ratio of blue to green fluorescence with a microplate reader (FLEX Station, Molecular Probes) (excitation: 405 nm; emission: blue, 460 nm, green, 530 nm). To control for the efficiency of core disassembly, the suspension was centrifuged at 13,800 Â g for 8 min at 4 8C to pellet the cores. The BlaM activity released into the supernatant was then measured after addition of 5 AM CCF2-FA to the supernatant and incubation for 3 and 6 h at room temperature. To control for the integrity of HIV-1 cores after a 6-h incubation, we measured the percentage of pelletable p24
Gag after centrifugation at 13,800 Â g for 8 min at 4 8C. As a negative control, viral cores were incubated with 0.1% Triton X-100 for 6 h at room temperature. The p24 Gag content of both the supernatant and the pellet was determined by enzyme-linked immunosorbent assay. Gag in 100 Al). Unactivated peripheral blood leukocytes (2 Â 10 6 ) were infected with p24 Gag (400 ng in 100 Al), washed once in CO 2 -independent DMEM (GIBCO BRL) to remove free virions, and loaded with CCF2-AM dye according to the manufacturer's instructions (Invitrogen). After two washes with DMEM, the cells were incubated for 7 to 16 h at room temperature in 200 Al of DMEM supplemented with 10% fetal bovine serum (FBS) and 2.5 mM probenecid, a nonspecific inhibitor of anion transport (Sigma). The cells were then washed once in DMEM and fixed in 1.2% paraformaldehyde overnight.
Virion-based fusion assay
The change in emission fluorescence of CCF2 dye after cleavage by BlaM-Vpr was monitored with a three-laser Vantage SE flow cytometer (Becton Dickinson, San Jose, CA). CCF2 was excited by 200 mW of 406.7 nm light from a krypton laser (Coherent). Blue emission was detected with an HQ455/50 filter and green emission with an HQ545/90 BP filter; light splitting was performed with a 505 SP filter. Data were collected with CellQuest and analyzed with FlowJo software (Treestar, San Carlos, CA). All filters were from Chroma Technology (Brattleboro, VT). In some experiments, digital images were obtained with a Nikon TE300 microscope equipped with a Hammamatsu ORCA II dual-scan, cooled CCD camera. CCF2 was excited with light from a mercury arc lamp filtered through Chroma D395X or D485X filters. Images were captured and processed with Universal Imaging MetaMorph (v4.6) and Adobe Photoshop.
Immunostaining
When the assay was applied to heterogeneous cell populations such as peripheral blood leukocytes, an immunostaining step was performed as described (Cavrois et al., 2004) before fixation of the cells to allow phenotyping of the subpopulations in which fusion had occurred. Standard immunostaining conditions were employed. Briefly, the cells were washed twice in staining buffer (PBS-2% FBS) and incubated for 30 min at room temperature with anti-CD3-APCCy7 diluted 1:20 in staining buffer. After two washes, the cells were fixed and analyzed by multiparameter flow cytometry.
Intracellular anti-p24
Gag staining
After two washes in PBS-2% FBS, the cells were permeabilized by incubation at room temperature for 30 min in PermeaFix (Ortho Diagnostic System, Raritan, NJ), washed twice, and incubated for 30 min at room temperature with anti-p24
Gag antibody (KC57) conjugated to FITC (1:20) and anti-CD3 conjugated to PE (1:100). After two washes, the cells were fixed and analyzed by multiparameter flow cytometry.
